VXRT
Aviragen Therapeutics Inc is a bio-pharmaceutical company. It is engaged in developing direct-acting antivirals to treat infections that affect a number of patients. It includes oral, small molecule compounds to treat infectious diseases.
Vaxart Inc (VXRT) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | B (3.4) | C- (2.0) | C (2.4) | C- (1.9) | C (2.5) |
| 2026-08-04 | C+ (2.7) | B (3.4) | C- (2.0) | C (2.4) | C- (1.9) | C (2.5) |
| 2026-08-03 | C+ (2.7) | C+ (2.7) | C (2.4) | C (2.4) | C- (2.0) | C (2.5) |
| 2026-07-29 | C+ (2.6) | C+ (2.5) | D+ (1.6) | D (1.2) | D+ (1.5) | C- (1.9) |
| 2025-06-30 | C+ (2.6) | C+ (2.5) | D+ (1.6) | D (1.3) | D+ (1.5) | C- (1.9) |